grant
Biomaterial-Enhanced CAR-T/NK Cell Therapies for Glioblastoma.
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 5 Mar 2026Deadline 28 Feb 2031
NIHUS FederalResearch GrantFY2026AbscissionAccess to CareAddressAgonistAlginatesAnimal ModelAnimal Models and Related StudiesAnimalsAntigen TargetingAntigensAscorbic AcidB7-H3B7H3Biocompatible MaterialsBioinformaticsBiomaterialsBiopolymersBrain NeoplasiaBrain NeoplasmsBrain TumorsCAR NKCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD276CD276 geneCell BodyCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCell TherapyCellsCellular FunctionCellular PhysiologyCellular ProcessClinicClinicalCommunicationDNA mutationDataDedicationsDevelopmentDextransDiseaseDisorderDrug DeliveryDrug Delivery SystemsDrugsEffectivenessElementsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpitope spreadingEvaluationExcisionExtirpationFDA approvedGenerationsGenetic ChangeGenetic defectGenetic mutationGliadelGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHealth Services AccessibilityHeterogeneityIFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune InterferonImmune mediated therapyImmune responseImmune systemImmunesImmunologically Directed TherapyImmunologyImmunostimulatory drugImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn SituInterferon GammaInterferon Type IIIntracellular Communication and SignalingMacrophageMedicationModelingMolecularMutationMφNK T cellNK T cell immunotherapyNK T cell therapyNK cell immune therapyNK cell immunotherapyNK cell therapyNK cell treatmentNK cell-based immune therapyNK cell-based immunotherapyNK cell-based therapyNK cell-based treatmentNK cellular immunotherapyNK cellular therapyNK immunotherapyNK therapyNK treatmentNKT cellNKT cell immunotherapyNKT cell therapyNatural Killer Cell ImmunotherapyNatural Killer T cellNatural Killer T cell TherapyPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPerioperativePharmaceutical PreparationsPorosityProcessProductionPrognosisR-Series Research ProjectsR01 MechanismR01 ProgramRadiationReceptor CellRemovalResearchResearch GrantsResearch Project GrantsResearch ProjectsResearch ProposalsResearch SupportSamplingSignal TransductionSignal Transduction SystemsSignalingStructureSubcellular ProcessSurgical RemovalSurvival RateSystemT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-cell therapeuticsT-cell transfer therapyTestingTransfectionTranslatingTumor CellVIT CVitamin CWorkaccess to health servicesaccess to servicesaccess to treatmentaccessibility to health servicesadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyantigen spreadingavailability of servicesbiocompatibilitybiological materialbiological signal transductionbiomaterial compatibilitycancer microenvironmentcare accesscell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapychemotherapychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor engineered natural killer cellchimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellschimeric antigen receptor natural killer cellsclinical applicabilityclinical applicationcontrolled releasecostdesigndesigningdevelopmentaldextrandrug/agentengineered T cellsepigeneticallygenetically engineered T-cellsgenome mutationglioblastoma multiformehealth service accesshealth services availabilityhost responseimmune stimulatory agentimmune stimulatory drugimmune stimulatory therapeuticimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunoresponseimmunostimulatory agentsimmunostimulatory biologicsimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedineffective therapiesineffective treatmentinnovateinnovationinnovativeinterstitiallFN-Gammamodel of animalmouse modelmultidisciplinarymurine modelnanofibernanofibrousnatural killer T cell immunotherapynatural killer T lymphocytenatural killer cell based immune therapynatural killer cell based immunotherapynatural killer cell therapynatural killer cell treatmentnatural killer cell-based therapynatural killer cells expressing chimeric antigen receptorsnatural killer cells with chimeric antigen receptorsnatural killer cellular therapynatural killer therapyneoplastic cellnovelpatient oriented outcomespre-clinicalpreclinicalprogramsresectionresponsescaffoldscaffoldingservice availabilityspongioblastoma multiformestandard of caretargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic T-cell platformtooltransgenic T- cellstranslational opportunitiestranslational potentialtreatment accesstumortumor microenvironmenttumors in the brain
Description preview
ABSTRACT
This comprehensive research program is focused on revolutionizing the treatment of Glioblastoma (GBM), a
highly aggressive brain tumor that currently has limited and largely ineffective treatment options. GBM is known
for its devastating impact on patients, often leading to poor prognosis and survival rates. The proposal brings
together a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click